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Abstract Objectives: This phase IIIb, open-label, multicentre, extension study (NCT01894919)
evaluated long-term antibody persistence and booster responses in participants who received a
reduced 2 + 1 or licensed 3 + 1 meningococcal serogroup B vaccine (4CMenB)-schedule (infants),
or 2-dose catch-up schedule (2–10-year-olds) in parent study NCT01339923.
Materials andmethods: Children aged 35months to 12 years (N = 851) were enrolled. Follow-on
participants (N = 646) were randomised 2:1 to vaccination and non-vaccination subsets; vacci-
nation subsets received an additional 4CMenB dose. Newly enrolled vaccine-naïve participants
(N = 205) received 2 catch-up doses, 1 month apart (accelerated schedule). Antibody levels were
determined using human serum bactericidal assay (hSBA) against MenB indicator strains for
fHbp, NadA, PorA and NHBA. Safety was also evaluated.
Results: Antibody levels declined across follow-on groups at 24–36 months versus 1 month
post-vaccination. Antibody persistence and booster responses were similar between infants
receiving the reduced or licensed 4CMenB-schedule. An additional dose in follow-on participants
induced higher hSBA titres than a first dose in vaccine-naïve children. Two catch-up doses in
vaccine-naïve participants induced robust antibody responses. No safety concerns were identified.
Conclusion: Antibody persistence, booster responses, and safety profiles were similar with
either 2 + 1 or 3 + 1 vaccination schedules. The accelerated schedule in vaccine-naïve children
induced robust antibody responses.
© 2017 GlaxoSmithKline SA. Published by Elsevier Ltd on behalf of The British Infection Associ-
ation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Invasive meningococcal disease (IMD) is a serious bacterial
infection caused by Neisseria meningitidis with more than
1.2million cases reported annually1 and a fatality rate ranging
from 10% to 40%.2 Disease progression is often very rapid.
Survivors may suffer from long-term complications such as
hearing impairment, seizures, amputations, and visual or
cognitive dysfunctions.2,3 The disease poses both a short-
and long-term clinical and financial burden and reduces the
quality of life of patients and their family members provid-
ing medical care. To lower the global clinical and economic
burden, vaccination has been deemed the most effective
strategy.2 Although 12 disease-causing serogroups exist world-
wide, serogroups A, B, C, W, X and Y account for almost all
IMD cases.1,4 Meningococcal serogroup B (MenB) causes a
significant proportion of IMD cases, with the highest inci-
dence in infants under 1 year of age, followed by 1–4-year-
olds and adolescents and recent outbreaks in various settings
(at university campuses, schools, child care institutions and
family clusters) in the United States and Europe have been
attributed to MenB.5–15 While meningococcal conjugate vac-
cines against serogroups A, C, W and Y have been available
for years, the development of a vaccine against serogroup B
has been more challenging due to the poor immunogenicity
and antigenic variability of the surface antigens.16 The first
vaccines against this serogroup were outer membrane vesicle
vaccines, which were only effective against homologous
serogroup B strains. Subsequently, twomulticomponent vac-
cines against serogroup B (4CMenB [Bexsero, GSK] and rLP2086
[Trumenba, Pfizer]) have been developed, each using a dif-
ferent approach to identify surface antigens.16,17
Previous studies have shown that 4CMenB vaccine is immu-
nogenicwith a clinically acceptable safety profilewhen admin-
istered as 3 doses during infancy with a booster dose in the
second year of life.18–22 This schedule has been approved in
several countries.23 In 2015, a reduced 2 + 1 dose schedule
(2, 4 and 12 months of age) was implemented in the infant
immunisation programme in the United Kingdom (UK)24,25
based on the preliminary results from a clinical trial evalu-
ating a 2 + 1-dose 4CMenB-schedule.26 This reduced 4CMenB-
schedule was shown to be 82.9% effective after 2 doses in
the eligible cohort within 10 months of 4CMenB implemen-
tation and, national surveillance is ongoing to evaluate the
long-term impact.26
Here, we present the results of an extension study, which
included children who received 4CMenB according to various
immunisation schedules in the parent study.27 The parent
study showed that the immune response to a reduced 2 + 1
dose infant vaccination schedule with 4CMenB was similar to
the response to a 3 + 1 dose schedule, and that a 2-dose
catch-up serieswas immunogenic in children aged 2–10 years.27
As for meningococcal conjugate vaccines, antibody waning
has been observed following administration of 4CMenB in
infants and young children.22,28–31 However, up to this date,
persistence data for a reduced 2 + 1 schedule are not avail-
able. This study assessed the antibody persistence up to 3
years after the completion of the different vaccination sched-
ules (3 + 1, 2 + 1 and catch-up) in the parent study as well as
the safety and tolerability of an additional 4CMenB dose.
Moreover, the immune response to a 2-dose accelerated
catch-up schedule of 4CMenB was evaluated in vaccine-
naïve children.
Materials and methods
Study design and participants
This phase IIIb, open-label, randomised, multicentre exten-
sion study (clinicaltrials.gov: NCT01894919) was conducted
in 9 centres in Hungary and 8 centres in Spain between June
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2013 and November 2015, in accordance with the principles
of Good Clinical Practice, the Declaration of Helsinki and all
applicable regulatory requirements. The study protocol and
its amendments were approved by local ethics committees
and regulatory authorities. Written informed consent was
obtained from the parents or legal guardians of each child
before enrolment. In addition, written informed assent was
obtained from each study participant eligible for informed
assent per local policies.
Healthy children aged 35–47 months to 12 years who had
completed different 4CMenB vaccination schedules in the
parent study (clinicaltrials.gov: NCT01339923) were enrolled
as “follow-on” participants in this extension study 24–36
months after vaccination completion (Fig. 1).
Follow-on participants who had received (i) 3 + 1 doses of
4CMenB at 2½, 3½, 5 and 11 months of age (Group 1), (ii)
2 + 1 doses of 4CMenB at 3½, 5 and 11 months of age (Group
2), or (iii) 2 + 1 doses of 4CMenB at 6, 8 and 11 months of age
(Group 3) were randomised (2:1) to vaccinated (Groups A, C,
and E, respectively) and unvaccinated (Groups B, D and F,
respectively) subsets. Follow-on participantswho had received
2 catch-up doses of 4CMenB 2 months apart at 2–5 years of
age (Group4a) or 6–10 years of age (Group4b)were randomised
(1:1 and 2:1 ratio, respectively) to vaccinated (Groups G and
I, respectively) and unvaccinated (Groups H and J, respec-
tively) subsets. Participants were randomised using an elec-
tronic randomisation system.
In addition, new vaccine-naïve participants were enrolled
in this study. They received 2 catch-up doses of 4CMenB
given 1 month apart (accelerated schedule). These partici-
pants were of similar age as follow-on participants from
Groups A to F: 35–47-month-olds were enrolled in Group K,
4–7-year-olds in group L, and 8–12-year-olds in Group M.
Detailed inclusion and exclusion criteria are presented in
Supplementary Text S1. The vaccine5 was administered intra-
muscularly into deltoid area of the non-dominant arm or in
the thigh for 2 participants.
Objectives
The primary immunogenicity objective of this extension study
was to evaluate the antibody persistence in children 24–36
months after 4CMenB vaccination in the parent study.
The secondary immunogenicity objectives were to eval-
uate (i) the immune response to an additional dose of 4CMenB
administered 24–36 months after vaccination in the parent
study; and (ii) the immune response to 2 catch-up doses of
4CMenB administered 1 month apart (accelerated schedule)
to healthy vaccine-naïve children. Safety objectives were (i)
to assess the safety and tolerability of 4CMenB when given as
an additional dose 24–36 months after vaccination in the
parent study, and (ii) to determine the safety and tolerabil-
ity of 2 catch-up doses of 4CMenB administered 1 month
apart to healthy vaccine-naïve children.
Immunogenicity assessment
For the follow-on participants, immune responses were evalu-
ated at the start of the extension study (Groups A–J) and at
Fig. 1. Study design. 3 + 1, 3 primary doses and a booster of 4CMenB; 2 + 1, 2 primary doses and a booster of 4CMenB; 2 + 0, 2 primary
doses of 4CMenB; Groups A, C, E, and G, I, follow-on vaccination groups who received an additional 4CMenB dose at month 0, 24–36
months after the last vaccination in the parent study and had blood draws at months 0 and 1; Groups B, D, F, H, and J, follow-on
non-vaccination groups who did not receive any vaccination in the extension study and only had blood draw at month 0; Groups K–M,
newly enrolled vaccine-naïve children who received 2 doses of 4CMenB 1 month apart (accelerated schedule) and had blood draws
at months 0, 1 and 2; the syringe indicates 4CMenB vaccination and the blood tube blood sampling; N, number of participants enrolled
per group; M, month(s); Y, years; AE, adverse event; SAE, serious AE; MAE, medically attended AE.
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1 month post-booster in the vaccinated subset (Groups A, C,
E, G and I). For the vaccine-naïve participants (Groups K–M),
immune responseswereevaluatedatbaseline (pre-vaccination)
and at 1 month after each dose of the 2-dose catch-up sched-
ule. Blood sampleswere collected at pre-specified time points
(Fig. 1) and were tested at GSK Clinical Laboratory Sciences,
Marburg, Germany (Neisseria heparin-binding antigen, NHBA)
or Public Health England Laboratory, Manchester, UK (factor
H-binding protein, fHbp; Neisserial adhesin A, NadA; Porin A
protein, PorA).
Serum bactericidal activity assays using human comple-
ment (hSBA) were used to measure the induction of func-
tional antibodies directed against 4 indicator strains of N.
meningitidis serogroup B: H44/76 for fHbp, 5/99 for NadA,
NZ98/254 for PorA and M10713 for NHBA.1
Safety assessment
Within Day 1–7 after each vaccination, solicited local and
systemic adverse events (AEs), other solicited data and all
unsolicited AEs were reported in participants from the vac-
cinated subset (Groups A, C, E, G, I) and vaccine-naïve par-
ticipants (Groups K, L, M) on diary cards. During the entire
study period, serious unsolicited AEs, medically attended
AEs and AEs leading to withdrawal from the study were col-
lected. All unsolicited AEs were monitored throughout the
study in participants included in the unvaccinated subset.
The severity of AEs and the possible relationship to study
vaccination were determined by the investigator.
Statistical analysis
Descriptive statistics were used for immunogenicity and safety
analyses and no statistical hypotheses testing were per-
formed. The immunogenicity analyses were based on the 3
full analysis sets (FAS) for persistence, booster or catch-up
and the safety analyses on the safety set (Supplementary
Text S2).
For immunogenicity endpoints, percentages of partici-
pants with hSBA titres ≥432 and associated 2-sided Clopper–
Pearson 95% confidence intervals (CIs) were computed by
vaccine group for each N. meningitidis serogroup B indicator
strain. Geometric mean titres (GMTs) and associated 2-sided
95% CIs were computed by exponentiating (base10) the cor-
responding least squaremeans of the log10-transformed titres
and associated 95% CIs were obtained from a 2-way analysis
of variance model having factors for vaccine group and study
centre.
All statistical analyses were performed using SAS version
9.2.
Results
Demographic characteristics
Out of 851 enrolled participants, 391 were assigned to the
follow-on vaccination subset, 255 to the follow-on unvacci-
nated subset, and 205 were vaccine-naïve participants. Eight
individuals terminated the study prematurely (Supplementary
Fig. S1). Demographic characteristics were similar across
groups (Supplementary Tables S1 and S2).
Immunogenicity
Long-term antibody persistence
At 24–36 months post-last vaccination in the parent study,
hSBA GMTs declined and percentages of children with hSBA
titres ≥4 decreased in all follow-on age groups compared to
1 month post-last vaccination (Table 1). In the follow-on
groups aged 35–47 months (Groups A–F), percentages of par-
ticipants with hSBA titres ≥4 ranged from 51%–61% for fHbp,
84%–93% for NadA, 38%–56% for PorA and 36%–45% for NHBA
(Table 1 and Supplementary Fig. S2A). The hSBA GMTs in
these follow-on groupswere similarwith overlapping CI against
each given strain. The percentages of children aged 4–7
years and 8–12 years in the follow-on groups (Groups G–J)
with hSBA titres ≥4 ranged from 52%–58% for fHbp, 79%–85%
for NadA, 29%–50% for PorA, and 42%–66% for NHBA at 24–36
months post-last vaccination in the parent study (Table 1
and Supplementary Fig. S2B).
In all age groups, both percentages of children with hSBA
titres ≥4 and GMT levels tended to be higher than baseline
percentages in the age-matched vaccine-naïve groups for
fHbp, NadA and PorA, but remained similar for NHBA (Table 1
and 2 and Supplementary Fig. S2).
Immunogenicity of an additional dose
The response to an additional 4CMenB dose against all indi-
cator strains was comparable between participants who had
received a reduced 2 + 1 (Groups C and E) or the licensed
3 + 1 dose schedule of 4CMenB vaccine (Group A), except for
NHBA, for which the immune response was higher in Group E
than Group A (Table 2 and Supplementary Fig. S3). An
additional4CMenB dose following 2 catch-up doses in the
parent study (GroupsG and I) induced robust booster responses
(Table 2). Across all age-matched groups, the percentages
of participants with hSBA antibody titres ≥4 and hSBA GMTs
tended to be higher in the follow-on groups at 1 month
post-booster (Groups A, C, E, G, I) than in vaccine-naïve
groups (Groups K–M) at 1 month post-dose 1 (Table 2).
Immunogenicity of a 2-dose catch-up
Across all vaccine-naïve groups (Groups K–M), the percent-
ages of participants with hSBA titres ≥4 increased substan-
tially between baseline and 1 month post-dose 1 for fHbp
(80%–95%), NadA (80%–93%) and PorA (70%–85%). Percent-
ages of participants with hSBA titres ≥4 against NHBA were
lower and ranged between 50% and 69% at 1 month post-dose
1. At 1month post-dose 2, 98%–100% of participants achieved
hSBA titres ≥4 against fHbp, all participants against NadA
and PorA, and 75%–80% against NHBA (Table 2 and
Supplementary Fig. S4). In the FAS for catch-up, all vaccine-
naïve participants demonstrated robust increases in hSBA
GMTs for fHbp, NadA and PorA, ranging from 34–46-fold for
fHbp, 242–558-fold for NadA, 27–30-fold for PorA and from
2.20–3.86 for NHBA at 1 month post-dose 2.
Reactogenicity
Solicited AEs
During the 7-day follow-up period post-booster, at least 1
solicited AEwas reported for 94%–97% of children in follow-on
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Table 1 Percentage of participants with hSBA titres ≥4 and geometric mean titres for antigens fHbp, NadA, PorA and NHBA at 1 month and 24–36 months post-vaccination in the
parent study (FAS cohort for Persistence).
Antigen Estimate Timing 35–47 M 4–7 Y 8–12 Y
Groups A + B Groups C + D Groups E + F Groups G + H Groups I + J
N Value (95% CI) N Value (95% CI) N Value (95% CI) N Value (95% CI) N Value (95% CI)
fHbp % ≥ 4 T1 137 100 (97.3–100.0) 129 100 (97.2–100.0) 118 100 (96.9–100.0) 67 100 (94.6–100.0) 173 99 (95.9–99.9)
T2 140 51 (42.8–60.0) 131 53 (43.8–61.5) 119 61 (52.0–70.1) 67 52 (39.7–64.6) 178 58 (50.3–65.2)
GMT T1 137 144 (120–171) 129 207 (172–250) 118 188 (155–229) 67 143 (112–182) 173 135 (115–158)
T2 140 4.17 (3.40–5.13) 131 4.48 (3.60–5.57) 119 5.62 (4.48–7.04) 67 3.97 (2.99–5.28) 178 5.75 (4.78–6.91)
NadA % ≥ 4 T1 136 100 (97.3–100.0) 130 100 (97.2–100.0) 118 100 (96.9–100.0) 66 98 (91.8–100.0) 176 99 (96.9–100.0)
T2 140 84 (77.2–89.9) 131 88 (80.9–92.9) 119 93 (87.2–97.1) 67 79 (67.4–88.1) 179 85 (79.4–90.3)
GMT T1 136 1898 (1571–2292) 130 1670 (1368–2040) 118 1518 (1235–1865) 66 475 (366–616) 176 441 (373–523)
T2 140 44 (32–60) 131 52 (37–72) 119 83 (58–117) 67 21 (14–33) 179 21 (16–28)
PorA % ≥ 4 T1 136 100 (97.3–100.0) 129 99 (95.8–100.0) 116 100 (96.9–100.0) 68 99 (92.1–100.0) 174 99 (96.8–100.0)
T2 140 45 (36.6–53.6) 131 38 (29.8–47.1) 119 56 (46.9–65.4) 68 29 (19.0–41.7) 179 50 (42.2–57.3)
GMT T1 136 58 (47–72) 129 79 (63–99) 116 71 (56–90) 68 46 (35–62) 174 48 (39–58)
T2 140 3.48 (2.78–4.36) 131 2.98 (2.35–3.78) 119 4.86 (3.80–6.22) 68 2.81 (2.07–3.82) 179 4.57 (3.74–5.59)
NHBA % ≥ 4 T1 105 86 (77.5–91.8) 84 89 (80.6–95.0) 78 88 (79.2–94.6) 61 90 (79.8–96.3) 160 96 (91.2–98.2)
T2 127 36 (27.9–45.2) 111 38 (28.8–47.5) 109 45 (35.4–54.8) 65 42 (29.4–54.4) 173 66 (58.9–73.5)
GMT T1 105 14 (11–18) 84 18 (13–24) 78 17 (12–23) 61 22 (15–30) 160 35 (28–44)
T2 127 2.77 (2.06–3.71) 111 3.03 (2.20–4.16) 109 3.17 (2.30–4.38) 65 3.53 (2.38–5.25) 173 7.82 (6.04–10)
Groups A + B, children who received 3 + 1 doses of 4CMenB in the parent study at age 2.5, 3.5, 5 and 11 months; Groups C + D, children who received 2 + 1 doses of 4CMenB at age 3.5, 5
and 11 months; Groups E + F, children who received 2 + 1 doses of 4CMenB at age 6, 8 and 11 months; Groups G + H, children who received 2 catch-up doses of 4CMenB at 2–5 years of age;
Groups I + J; children who received 2 catch-up doses of 4CMenB at 6–10 years of age; T1, 1 month after last vaccination in the parent study; T2, 24–36 months after last vaccination in the
parent study; FAS, full analysis set; CI, confidence interval; N, number of participants in each group with available results; M, months; Y, years; hSBA, serum bactericidal activity assay using
human complement; GMT, geometric mean titre; fHbp, factor H binding protein; NadA, neisserial adhesin A; PorA, porin A protein; NHBA, neisserial heparin binding antigen.
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Table 2 Percentage of participants with hSBA titres ≥4 and geometric mean titres for antigens fHbp, NadA, PorA and NHBA at 24–36 months post-vaccination in the parent study and
at 1 month post-booster for follow-on participants and at baseline and post-catch-up dose 1 (FAS cohort booster) and 2 for vaccine-naïve participants (FAS cohort for catch-up).
Follow-on participants Vaccine-naïve participants
35–47
M
4–7
Y
8–12
Y
35–47
M
4–7
Y
8–12
Y
Group A Group C Group E Group G Group I Group K Group L Group M
Antigen Estimate Timing Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
fHbp % ≥ 4 T1 48 (37.3–58.5)
92
51 (40.1–62.1)
86
64 (52.1–74.8)
75
39 (21.8–57.8)
31
59 (48.5–69.5)
91
39 (28.8–49.0)
96
27 (16.1–41.0)
55
20 (10.0–33.7)
50
T2 99 (94.3–99.97)
96
100 (95.8–100.0)
86
100 (95.2–100.0)
75
97 (83.8–99.9)
32
99 (94.0–99.97)
91
95 (88.3–98.3)
96
91 (80.0–97.0)
55
80 (66.3–90.0)
50
T3 - - - - - 100 (96.3–100.0)
98
98 (90.1–99.95)
54
100 (92.7–100.0)
49
GMT T1 3.91 (3.01–5.08)
92
4.84 (3.66–6.41)
86
6.21 (4.65–8.31)
75
3.14 (2.08–4.75)
31
6.15 (4.77–7.93)
90
2.82 (2.26–3.50)
96
2.33 (1.77–3.07)
55
1.93 (1.39–2.68)
50
T2 158 (116–215)
96
205 (147–287)
86
288 (204–408)
75
155 (95–252)
32
258 (190––349)
91
14 (11–17)
96
16 (12–23)
55
13 (8.67–20)
50
T3 - - - - - 107 (84–135)
98
74 (56–99)
54
63 (47–85)
49
NadA % ≥ 4 T1 84 (74.5–90.6)
92
91 (82.7–95.9)
87
95 (87.1–98.5)
76
74 (55.4–88.1)
31
86 (76.8–92.2)
91
3 (0.6–8.9)
96
4 (0.44–12.5)
55
8 (2.2–19.2)
50
T2 99 (94.3–99.97)
96
99 (93.8–99.97)
87
97 (90.8–99.68)
76
100 (89.1–100.0)
32
100 (96.0–100.0)
91
88 (79.2–93.4)
96
93 (82.4–98.0)
55
80 (66.3–90.0)
50
T3 - - - - - 100 (96.3–100.0)
98
100 (93.4–100.0)
54
100 (92.7–100.0)
49
GMT T1 39 (26–58)
92
53 (35–82)
87
89 (57–139)
76
19 (9.92–35)
31
22 (15–32)
91
1.15 (1.02–1.29)
96
1.20 (0.96–1.51)
55
1.38 (1.10–1.73)
50
T2 2908 (2059–4107)
96
3593 (2474–5218)
87
3677 (2495–5419)
76
3205 (1860–5526)
32
2921 (2079–4104)
91
38 (28–54)
96
27 (18–40)
55
20 (12–33)
50
T3 - - - - - 631 (503–792)
98
421 (319–555)
54
317 (238–423)
49
PorA % ≥ 4 T1 45 (34.2–55.3)
92
42 (31.3–53.0)
86
52 (40.2–63.7)
75
25 (11.5–43.4)
32
47 (36.7–58.0)
91
2 (0.25–7.3)
96
7 (2.1–17.9)
54
6 (1.3–16.5)
50
T2 99 (94.3–99.97)
96
100 (95.8–100.0)
86
100 (95.2–100.0)
75
100 (89.1–100.0)
32
100 (96.0–100.0)
91
78 (68.5–85.9)
96
85 (72.9–93.4)
54
70 (55.4–82.1)
50
T3 - - - - - 100 (96.3–100.0)
98
100 (93.4–100.0)
54
100 (92.6–100.0)
48
GMT T1 3.41 (2.57–4.54)
92
3.17 (2.34–4.31)
86
4.86 (3.54–6.67)
75
2.99 (1.92–4.65)
32
4.49 (3.40–5.92)
91
1.14 (1.06–1.23)
96
1.35 (1.15–1.59)
54
1.22 (1.06–1.41)
50
T2 92 (70–122)
96
91 (68–123)
86
133 (97–181)
75
71 (46–110)
32
82 (63–108)
91
6.94 (5.60–8.59)
96
13 (8.88–19)
54
8.56 (5.51––13)
50
T3 - - - - - 34 (27–42)
98
37 (28–49)
54
34 (26–46)
48
(continued)
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Table 2 (continued)
Follow-on participants Vaccine-naïve participants
35–47
M
4–7
Y
8–12
Y
35–47
M
4–7
Y
8–12
Y
Group A Group C Group E Group G Group I Group K Group L Group M
Antigen Estimate Timing Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
Value (95% CI)
N
NHBA % ≥ 4 T1 38 (27.7–50.2)
78
37 (25.4–49.3)
68
49 (36.6–61.9)
65
28 (12.7–47.2)
29
69 (58.1–78.5)
87
44 (33.2–55.3)
84
45 (30.7–59.8)
49
63 (47.5–76.8)
46
T2 75 (64.6–83.6)
88
84 (73.5–90.9)
79
97 (89.6–99.64)
67
93 (77.9–99.2)
30
96 (88.9–98.8)
89
50 (39.1–60.9)
88
69 (54.1–80.9)
51
68 (52.9–80.9)
47
T3 - - - - - 77 (66.9–85.1)
91
75 (61.1–86.0)
52
80 (65.7–89.8)
49
GMT T1 3.05 (2.08–4.46)
78
3.10 (2.05–4.68)
68
3.58 (2.35–5.45)
65
2.31 (1.29–4.13)
29
7.83 (5.52–11)
87
3.53 (2.64–4.71)
84
4.80 (2.86–8.06)
49
7.70 (4.55–13)
46
T2 13 (9.15–18)
88
18 (13–26)
79
40 (27–59)
67
32 (19–54)
30
53 (38–73)
89
4.92 (3.39–7.13)
88
9.44 (5.84–15)
51
12 (6.61–21)
47
T3 - - - - - 12 (7.57–18)
91
11 (6.87–19)
52
14 (8.34–24)
49
Group A, children who received 3 + 1 doses of 4CMenB in the parent study at age 2.5, 3.5, 5 and 11 months; Group C, children who received 2 + 1 doses of 4CMenB at age 3.5, 5 and 11 months;
Group E, children who received 2 + 1 doses of 4CMenB at age 6, 8 and 11 months; Group G, children who received 2 catch-up doses of 4CMenB at 2–5 years of age; Group I, children who
received 2 catch-up doses of 4CMenB at 6–10 years of age; T1, 24–36 months after last vaccination in the parent study (Groups A, C, E, G, I) or baseline (Groups K–M); T2, 1 month
post-booster (Groups A, C, E, G, I) or 1 month post-catch-up dose 1 (Groups K–M); T3, 1 month post-catch-up dose 2 (Groups K–M); FAS, full analysis set; CI, confidence interval; N, number
of participants in each group with available results; M, months; Y, years; hSBA, serum bactericidal activity assay using human complement; GMT, geometric mean titre; fHbp, factor H
binding protein; NadA, neisserial adhesin A; PorA, porin A protein; NHBA, neisserial heparin binding antigen.
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groups. In vaccine-naïve groups, the percentage of participants
experiencing at least 1 solicited AE tended to decrease post-
dose 2 compared to post-dose 1. From day 1 to day 7 post-
dose 1 and 2, at least 1 solicited AE was reported for 93% and
82% of participants in Group K, all participants and 93% in
Group L, and 98% and 90% of participants in Group M, respec-
tively. The most commonly reported local reactions after
any vaccination were injection-site pain in Groups I and M,
and tenderness in Groups A, C, E, G, K and L (Fig. 2). The
most frequent systemic reaction was irritability in Groups A,
C, E, G, K, and L. Malaise and headache were the most
common systemic reactions in Group I, and headache in
Group M (Fig. 3).
Unsolicited AEs
Across the follow-on Groups, unsolicited AEs post-booster
were reported for 15% to 33% of participants. Out of these,
8% to 19% were considered at least possibly related to vac-
cination by the investigator. In the vaccine-naïve Groups K
and M, 15% and 12% (post-dose 1) and, 12% and 8% (post-dose
2) of participants reported unsolicited AEs; in Group L this
was 13% post-dose 1 and 2. Out of these, 5%–11% post-dose 1
and 6%–9% post-dose 2 were possibly related to vaccination.
Across all groups, the most commonly reported unsolicited
AEs as per system organ class were “infections and infesta-
tions” and “general disorders and administration site
conditions”.
The majority of unsolicited AEs at least possibly related
to vaccination were solicited local and systemic AEs that
continued beyond day 7 after vaccination. There were no
serious AEs and deaths reported in this study.
Discussion
Our novel data show that a reduced 2 + 1 4CMenB vaccina-
tion series in infants produces protective antibody levels
similar to the licensed 3 + 1 schedule. These results suggest
that the schedule (2 + 1 or 3 + 1) does not impact the
antibody persistence 24–36months post-vaccination in young
infants. This is also the first study presenting data on anti-
body persistence 24–36 months following a 2-dose catch-up
vaccination series, with similar bactericidal antibody levels
against each given strain in children who had received 2
catch-up doses at 2–5 years and 6–10 years in the parent
study. The GMTs and the percentages of participants with
Fig. 2. Solicited local reactions after 4CMenB booster vaccination for follow-on participants (A), and after dose 1 (left panel) and
after dose 2 (right panel) for vaccine-naïve participants (B). Group A, children 35–47 months of age who received 3 + 1 doses of
4CMenB in the parent study; Groups C and E, children 35–47 months of age who received 2+1 doses of 4CMenB in the parent study;
Group G, children 4–7 years of age who received 2 catch-up doses of 4CMenB in the parent study; Group I, children 8–12 years of age
who received 2 catch-up doses of 4CMenB in the parent study; Group K, naïve children 35–47 months of age; Group L, naïve children
4–7 years of age; Group M, naïve children 8–12 years of age.
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hSBA titres ≥4 were generally higher among follow-on par-
ticipants at 24–36 months post-vaccination as compared to
the baseline antibody levels in vaccine-naïve children (except
for NHBA).
The presence of functional circulating antibodies mea-
sured by hSBA is a main factor contributing to the duration
of protection against IMD. It is particularly important to
ensure protection of children under 5 years, who are the
most susceptible for IMD.33 Waning antibody titres following
immunisation with 4CMenB have been observed in other
clinical studies.22,28–31 Whether the observed decline in anti-
bodies translates in reduced vaccine effectiveness is not
clear. The first vaccine effectiveness data after 4CMenB
implementation in the UK was recently reported to be 82.9%
Fig. 3. Solicited systemic reactions after 4CMenB booster vaccination for follow-on participants (A), and after dose 1 (B) and after
dose 2 (C) for vaccine-naïve participants. Group A, children 35–47 months of age who received 3 + 1 doses of 4CMenB in the parent
study; Groups C and E, children 35–47 months of age who received 2+1 doses of 4CMenB in the parent study; Group G, children 4–7
years of age who received 2 catch-up doses of 4CMenB in the parent study; Group I, children 8–12 years of age who received 2
catch-up doses of 4CMenB in the parent study; Group K, naïve children 35–47 months of age; Group L, naïve children 4–7 years of age;
Group M, naïve children 8–12 years of age.
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after 2-dose priming.26 In Canada, 4CMenB has been used in
amass immunisation campaign in individuals between2months
and 20 years of age to control a regional outbreak of serogroup
B disease in the Saguenay–Lac-Saint-Jean region.34 Two years
after the start of this campaign, no IMD cases due to serogroup
B occurred in the vaccinated and unvaccinated target pop-
ulation, and multivariate analysis showed a statistically sig-
nificant decrease in MenB IMD rate in the region.34 Longer
follow-up data will become available as the vaccine is intro-
duced in other countries.
Persistence data regarding the other licensed protein-
based serogroup B vaccine, rLP2086, have so far only been
reported for one study performed in a different age group
(adolescents aged 11–18 years): up to 4 years after a 3-dose
schedule, protective hSBA titres were elicited in at least 50%
of adolescents against 3 of 4 meningococcal serogroup B test
strains.35 The antibody persistence data following meningo-
coccal serogroup B protein-based vaccines seem to follow a
similar pattern to that of quadrivalent meningococcal con-
jugate vaccines or meningococcal C conjugate vaccines.36–38
At 24–36months after last vaccination in the parent study,
the administration of an additional 4CMenB dose in previ-
ously primed participants (follow-on groups) showed a stron-
ger immune response with a higher increase of hSBA titres,
as compared to a first dose of 4CMenB in age-matched vaccine-
naïve participants (except for NHBA). This robust immune
response triggered by administration of an additional 4CMenB
dose indicated that initial vaccination in the parent study
had resulted in successful immune memory. Anamnestic
responses to a booster dose of 4CMenB vaccine (fifth dose)
have also been described in another clinical study.28
While the hSBA assay offers information on the immunity
of individuals, it fails to provide a comprehensive population-
wide overviewbecause other factors such as immunememory,
herd immunity and bacterial carriage also impact long-term
protection. For instance, in the UK, waning antibody titres
have been reported for meningococcal serogroup C vaccina-
tion but catch-up campaigns among children, teenagers and
young adults resulted in herd immunity, which vigorously
contributed to the effectiveness of the immunisation
programme.39 The influence of 4CMenB vaccination on naso-
pharyngeal carriage and its ability to induce herd immunity
is currently not well-known. One randomised clinical study
found that 4CMenB, as well as the quadrivalent meningococ-
cal conjugate vaccine MenACWY-CRM, modestly reduced
meningococcal carriage in UK university students from 3 to
12months post-vaccination, but found no correlation between
post-vaccination hSBA titres and carriage.40,41 Active surveil-
lance will be key to ascertain the clinical impact of antibody
persistence and real-life effectiveness data will help to for-
mulate the most efficient disease control.
This study is the first evaluation of an accelerated 2-dose
catch-up schedule with 4CMenB (given 1 month apart) in
vaccine-naïve participants at either 35–47 months of age,
4–7 years of ageor 8–12 years of age. Robust antibody responses
were induced against all strains (except for a lower response
against NHBA), with an early response after the first dose.
This accelerated schedule may be used as a measure to
control disease outbreaks or for people that face imminent
exposure such as travellers to risk areas and emergency
responders in disaster zones. Vaccination with 4CMenB has
already been used in response to MenB outbreaks at university
campuses in the United States14,15 and in Quebec (Canada)
following increased MenB incidences.34 The use of an accel-
erated 2-dose schedule inducing robust immune responses
allows for a rapid intervention with the promise to confer
protection.
The lower performance of NHBA might result from high
pre-vaccination titres as observed in previous studies.28,31
Many vaccine-naïve children had baseline hSBA titres ≥1:4
against NHBA, suggesting that M10713 is particularly sensi-
tive to killing within the assay.31
The tolerability profile of 4CMenB vaccine was accept-
able, similar to previous studies, and no major safety con-
cerns were identified after an additional4CMenB dose in
follow-on participants or after 2 catch-up doses in vaccine-
naïve children. Similar percentages of participants reported
local and systemic reactions after vaccination. The majority
of unsolicited reactions were mild in nature, most of them
were solicited AEs persisting beyond day 7 post-vaccination.
While in a different study systemic reactogenicity was lowest
in vaccine-naïve two-year-olds, followed by infants and tod-
dlers, local reactogenicity was common in all groups.29 In
5-year-old children, a fifth dose of 4CMenB was well toler-
ated, although injection-site pain was noteworthy.30 In line
with these results, real-life experience with 4CMenB in the
UK or Canada has been reassuring in terms of safety data and
no new safety concerns have been identified.16 Ongoing post-
licensure surveillance after widespread use of 4CMenB will
be important to identify any possible safety signals.
As a drawback of the study, the low number of partici-
pants, due to loss of follow-up from the parent study, might
limit interpretation. However, the design of the extension
study further allows elaborating on the immunogenicity of a
booster response in children who received different 4CMenB
vaccination schedules.
Conclusions
A reduced 2 + 1 4CMenB primary vaccination schedule resulted
in similar antibody persistence compared to the licensed
3 + 1 schedule, and no safety concern was observed for
either schedules. Both vaccination schedules triggered a com-
parably strongbooster response. Twocatch-updoses of 4CMenB
at an accelerated schedule in vaccine-naïve participants
induced robust antibody responses.
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